Anititumoral ecteinascidin derivatives

Details Anititumoral ecteinascidin derivatives Anititumoral ecteinascidin derivatives

2011-04-05

2011-04-05

Ward, Paul V. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S338000

Reexamination Certificate

active

07919493

ABSTRACT:
This invention relates to antitumoral ecteinascidin derivatives that contain a fused ecteinascidin five ring system with a 1,4-bridge having the structure of formula (VIa) or (VIb) as described herein and compounds in which the —NH2or —OH of the 1,4-bridge is derivatized, and related pharmaceutical compositions and methods. Such ecteinascidin derivatives include, but are not limited to, those compounds having formula (XVIIb):in which R1and R4together form a group of formula (VIa) or (VIb) as described herein, and R5, R7, R8, R14a, R14b, R15, and R21are as defined herein.

REFERENCES:
patent: 5089273 (1992-02-01), Rinehart et al.
patent: 5149804 (1992-09-01), Rinehart et al.
patent: 5256663 (1993-10-01), Rinehart et al.
patent: 5478932 (1995-12-01), Rinehart et al.
patent: 5654426 (1997-08-01), Rinehart et al.
patent: 5721362 (1998-02-01), Corey et al.
patent: 5985876 (1999-11-01), Rinehart et al.
patent: 6124292 (2000-09-01), Corey
patent: 6124293 (2000-09-01), Rinehart
patent: 6316214 (2001-11-01), Rinehart
patent: 6348467 (2002-02-01), Corey
patent: 6544560 (2003-04-01), Bullent
patent: 6569859 (2003-05-01), Corey
patent: 6686470 (2004-02-01), Danishefsky et al.
patent: 6712023 (2004-03-01), Targotay
patent: 6815544 (2004-11-01), Corey
patent: 6867334 (2005-03-01), Rinehart
patent: 7115743 (2006-10-01), Rinehart
patent: 7202361 (2007-04-01), Flores et al.
patent: 7241892 (2007-07-01), Cuevas
patent: 7247629 (2007-07-01), Manzanares
patent: 7410969 (2008-08-01), Manzanares
patent: 7420051 (2008-09-01), Francesch
patent: 7524956 (2009-04-01), Cuevas
patent: 2003/0216397 (2003-11-01), Flores
patent: 2004/0002602 (2004-01-01), Francesch
patent: 2004/0019056 (2004-01-01), Manzanares et al.
patent: 2008/0234279 (2008-09-01), Rinehart
patent: 0 309 477 (1991-11-01), None
patent: 59-225189 (1984-12-01), None
patent: 60-84288 (1985-05-01), None
patent: WO 87/07610 (1987-12-01), None
patent: WO 92/09607 (1992-06-01), None
patent: WO 98/12198 (1998-03-01), None
patent: WO 98/46080 (1998-10-01), None
patent: WO 99/58125 (1999-11-01), None
patent: WO 00/18233 (2000-04-01), None
patent: WO 00/69862 (2000-11-01), None
patent: WO 01/77115 (2001-10-01), None
patent: WO 01/87894 (2001-11-01), None
patent: WO 01/87895 (2001-11-01), None
patent: WO 2009/050303 (2009-04-01), None
patent: WO 2009/138509 (2009-11-01), None
patent: WO 2009/140675 (2009-11-01), None
Pinedo et al., “Translational Research . . . ”, TheOncologist 2000,, 5 (suppl1): 1-2 (www.The Oncologist.com).
McMahon, Gerald, “VEGF Receptor Signaling in Tumor Angiogenesis”, the Oncologist 2000; 5(suppl 1): 3-10 (www.TheOncologist.com).
Pinedo et al., “Translational Research . . . ”, The Oncologist 2000,, 5 (suppI1): 1-2 (www.The Oncologist .com).
McMahon, Gerald, “VEGF Receptor Signaling in Tumor Angiogenesis”, The Oncologist 2000; 5(suppl 1): 3-10 (www.TheOncologist.com).
Pommier, Yves et al., “DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia Turbinata”,Biochemistry, vol. 35, pp. 13303-13309 (1996).
Pretsch et al.,Tables of Spectral Data for Structure Determination of Organic Compounds, pp. H125 (1983).
Reid, Joel M. et al., “Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity”,Cancer Chemotherapy and Pharmacology, vol. 38, No. 4, pp. 329-334 (1996).
Remers, William A., “Saframycins, Renieramycins, and Safracins”,The Chemistry of Antitumor Antibiotics, vol. 2, pp. 93-119 (1988).
Rinehart et al., “Novel Bioactive Natural Products from Marine Organisms”,Topics in Pharmaceutical Sciences 1989, pp. 613-626, D.D. Breimer, D.J.A. Cromwelin, K.K. Midha, Eds., Amsterdam Medical Press B.V. Noordwijk, The Netherlands (1989).
Rinehart, Kenneth L. et al., “Applications of High-Resolution Tandem FAB Mass Spectrometry”,Biological Mass Spectrometry, eds. Burlingame et al., Elsevier Amsterdam, pp. 233-258 (1990).
Rinehart, Kenneth L. et al., “Biologically active natural products”,Pure and Applied Chemistry, vol. 62, No. 7, pp. 1277-1280 (1990).
Rinehart, Kenneth L. et al., “Bioactive Compounds from Aquatic and Terrestrial Sources”,Journal of Natural Products, vol. 53, No. 4, pp. 771-792 (1990).
Rinehart, Kenneth L., “Antitumor Compounds from Tunicates”,Medicinal Research Reviews, vol. 20, No. 1, pp. 1-27 (2000).
Rinehart, Kenneth L. et al., “Ecteinascidins 729, 743, 759A , 759B, and 770: Potent Antitumor Agents from the Caribbean Tunicate Exteinascidia Turbinata”,The Journal of Organic Chemistry, vol. 55, No. 15, pp. 4512-4515 (1990).
Saito, Naoki et al., “Synthesis of Saframycins. 3. Preparation of a Key Tricyclic Lactam Intermediate to Saframycin A”,The Journal of Organic Chemistry, vol. 54, No. 22, pp. 5391-5395 (1989).
Sakai, Ryuichi et al., “Ecteinascidins: Putative Biosynthetic Precursors and Absolute Stereochemistry”,Journal of the American Chemical Society, vol. 118, No. 38, pp. 9017-9023 (1996).
Sakai, Ryuichi et al., “Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo”,Proceedings of the National Academy of Sciences, vol. 89, No. 23, pp. 11456-11460 (1992).
Shamma, Maurice et al.,Carbon-13 NMR Shift Assignments of Amines and Alkaloids, pp. 206 (1979).
Still, W. Clark et al., “Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution”,Journal of Organic Chemistry, vol. 43, No. 14, pp. 2923-2925 (1978).
Takahaski, Katsuhiro, “New Antibiotics, Saframycins A, B, C, D and E”,The Journal of Antibiotics, vol. XXX, No. 11, pp. 1015-1018 (1977).
Takahaski, Katsuhiro et al., “Microbial Conversion of Saframycin A to 25-Dihydrosaframycin A and 21-Decyano-25-Dihydrosaframycin A (25-Dihydrosaframycin B) and Their Biological Activities”,The Journal of Antibiotics, vol. XXXV, No. 2, pp. 196-202 (1982).
Trowitzsch-Kienast, Wolfram et al., “Isolierung und Strukturaufklarung der Saframycine Mx 1 und Mx 2, neue antitumor-aktive Antibiotika aus Myxococcus xanthus”,Liebigs Ann. Chem., vol. XXXV, pp. 475-481 (1988).
Valoti et al., “Ecteinascidin-743, a New Marine Natural Product with Potent Antitumor Activity on Human Ovarian Carcinoma Xenografts”, Clin. Cancer Res. 4 (8): 1977-83, 1998.
Witten, Jane L. et al., “Structures of Two Cockroach Neuropeptides Assigned by Fast Atom bombardment Mass Spectrometry”,Biochemical and Biophysical Research Communications, vol. 124, No. 2, pp. 350-358 (1984).
Wright, Amy E. et al., “Antitumor Tetrahydroisoquinoline Alkaloids from the Colonial Ascidian Ecteinascidia Turbinata”,The Journal of Organic Chemistry, vol. 55, No. 15, pp. 4508-4512 (1990).
Yazawa, Katsukiyo et al., “Bioconversions of Saframycin a Specific to some Genera of Actinomycetes”,The Journal of Antibiotics, vol. XXXV, No. 7, pp. 915-917 (1982).
Yazawa, Katsukiyo et al., “Isolation and Structural Elucidation of New Saframycins Y3, Yd-1, Yd-2, Ad-1, Y2b and Y2b-d”,The Journal of Antibiotics, vol. XXXIX, No. 12, pp. 1639-1650 (1986).
Zmijewski, Milton J., Jr. et al., “The in vitro Interaction of Naphthyridinomycin with Deoxyribonucleic Acids”,Chemico-Biological Interactions, vol. 52, No. 3, pp. 361-375 (1985).
Suggitt et al., “50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches,” Clinical Cancer Research, vol. 11, Feb. 1, 2005, pp. 971-981.
U.S. Appl. No. 10/485,536, filed May 18, 2005, Pilar Gallego.
U.S. Appl. No. 10/503,106, filed Jun. 8, 2005, Valentin Martinez Barrasa.
U.S. Appl. No. 12/273,919, filed Nov. 19, 2008, Valentin Martinez Barrasa.
U.S. Appl. No. 11/769,873, filed Jun. 28, 2007, Esteban Cvitkovich.
U.S. Appl. No. 10/738,973, filed Dec. 17, 2003, Elias J. Corey.
U.S. Appl

Affiliated with

Also associated with

Rating

Anititumoral ecteinascidin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anititumoral ecteinascidin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anititumoral ecteinascidin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2707668